BRIDGE study published: Cangrelor suited for important antiplatelet niche

Boston, MA - The BRIDGE study, showing that the intravenous P2Y12 receptor antagonist cangrelor (the Medicines Company) could represent an effective bridging therapy for patients taking thienopyridine antiplatelet agents such as clopidogrel who are scheduled for surgery, has been published in the January 18, 2012 issue of the Journal of the American Medical Association.

See the study athttp://www.theheart.org/article/1341135.do?utm_campaign=newsletter&utm_medium=email&utm_source=20120118_EN_Heartwire